

Sheet 1 of 1							
FORM PTO 1449 (modified)			ATTY DOCKET NO.: SERI		AL NO.:		
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			P66141US0 09/701,583				
			APPLICANT: Karl Herman SCHLINGENSIEPEN et al				
	RENCES CITED BY APPLICAN several sheets if necessary)	T(S)			מסא ר	2 5 20 01	
Date Submitted to PTO: April 24, 2001			FILING DATE:		GROUP:		
Date Statistics to 190 spin 2 years			February 5, 2001		1632 Julien 1600/2900		
U.S. PATENT DOCUMENTS							
•EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
					 		
				 			
				 			
				 		· · · · · ·	
		5005	ICN DATENT DOCUMENT	<u> </u>			
	DOGUNATATE	IGN PATENT DOCUMENT COUNTRY	CLASS	SUBCLASS	TRANSLATION		
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SOBCEASS	YES NO	
3	WO 96/02143	02/1996	WIPO		>		
010	WO 94/25588	11/1994	WIPO				
	WO 95/00103	01/1995	WIPO				
				ļ			
			<u> </u>	<u> </u>		1	
OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.)							
Piotr JACHIMCZAK et al., "The Effect of Transforming Growth Factor-β ₂ Specific Phosphorothioate-anti-sense Oligodeoxym Reversing Cellular immunosuppression in Malignant Glioma", Vol. 78, Pages 944-951, June 1993. Maureen SPEARMAN et al., "Antisense Oligodeoxyribonucleotide Inhibition of TGF-β ₁ Gene Expression and Alterations in the malignant Properties of mouse Fibrosarcoma Cells", Vol. 149, No. 1, Pages 25-29, November 1994.						godeoxynucleotides in	
						ations in the Growth and	
		XP-000886176, "Concomitant Expression of Interferon-γ and Antisense TGF-β Transgenes Enhances the Immunogenicity of a Murine					
\\		Mammary Carcinoma", November 1997.					
							
EXAMINER DATE CONSIDERED							
EXAMINER DATE SONSIDERED 3/28/05							
							

• EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.